Effects of gene polymorphisms in drug metabolism and transport on population pharmacokinetics and adverse in patients treated with docetaxel.

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025026

Enrollment

Unknown

Registered

2019-08-08

Start date

2019-08-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid tumor

Interventions

sigle arm:docetaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years. 2. Normal liver and kidney function. 3. Clinical diagnose solid tumor, patients with cytological or histological confirmation for chemotherapy with docetaxel.

Exclusion criteria

Exclusion criteria: 1. Patients with history of liver disease. 2. Patients lost to follow-up. 3. The investigator believes that it is not suitable for patients participating in this trial.

Design outcomes

Primary

Measure	Time frame
plasma concentration of docetaxel;CYP3A5, ABCB1, ABCC2, SLCO1A2, SLCO1B1, SLCO1B3;	—

Countries

China

Contacts

Public ContactQian Du

The Third Affiliated Hodpital of Chongqing Medical University (Gener Hospital)

duqian331100@sina.com+86 18580504277

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026